Advertisement
Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
read more
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
vor 437 Tagen
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
vor 471 Tagen
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
vor 618 Tagen
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
vor 1199 Tagen
Asian Markets A Sea Of Red
Asian stock markets are a sea of red on Monday, following the broadly negative cues from Wall Street on Friday, amid renewed U.S.-China trade war after US President Donald Trump threatened to massively increase tariffs on China in retaliation for China's expansive export curbs on its rare earth minerals, which are essential for manufacturing and technology.
RTTNews
|
vor 12 Minuten
Sensex, Nifty Seen Opening Lower After Wall Street Rout
Indian shares look set to open lower on Monday as investors fret about an escalation of the trade war between U.S. and China and the potential impact on the global economy.
RTTNews
|
vor 37 Minuten
Indonesia Shares Likely To Open Under Water On Monday
The Indonesia stock market has moved higher in two straight sessions, collecting more than 90 points or 1.1 percent along the way. Now at a fresh record closing high, the Jakarta Composite Index sits just beneath the 8,260-point plateau although it's overdue for profit taking on Monday.
RTTNews
|
vor 1Std 43 Minuten
Hong Kong Shares Tipped To Open Under Pressure On Monday
The Hong Kong stock market had moved lower in five straight sessions, shedding almost 1,000 points or 3.6 percent along the way. The Hang Seng Index now sits just above the 26,290-point plateau and it may extend its slide on Monday.
RTTNews
|
vor 1Std 58 Minuten
